1,102 results on '"Bashey, Asad"'
Search Results
102. Calcineurin Inhibitor–Free Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Brief-Course Sirolimus Following Reduced-Intensity Peripheral Blood Stem Cell Transplantation
103. Current Status of BoneMarrow Transplantation for Treatment of Cancer
104. Graft-versus-host disease prophylaxis
105. Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma
106. Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of a Prospective Phase II Trial
107. Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma.
108. 493 - Let’s Get Serial: Detection and Monitoring of Mucormycosis in Hematopoietic Stem Cell Transplant Recipients with the Karius Test™
109. Correction: The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation
110. Effect of Early Post-Transplant Respiratory Viral Infections on Graft-Versus-Host Disease (GVHD) and Other Transplant Outcomes
111. Outcomes of MDS and AML Patients with TP53 Gene Mutation Receiving Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
112. Allogeneic Hematopoietic Cell Transplantation (HCT) for Adult Patients with Acute Lymphoblastic Leukemia: Impact of Timely Transplantation on Survival Outcomes
113. Disease-Specific Pathways for NK Cell Alloreactivity Informs Relapse Risk after Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide: Relative Effect of Recipient HLA-C-Group KIR Ligand and HLA-B-Leader Allotype
114. Let’s Get Serial: Detection and Monitoring of Mucormycosis in Hematopoietic Stem Cell Transplant Recipients with the Karius Test™
115. Post-Transplant Maintenance in AML and MDS Patients Undergoing Non-Myeloablative Peripheral Blood Stem Cell Transplant with Post-Transplant Cyclophosphamide
116. Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
117. Reduced-Intensity Allogeneic Transplantation Provides High Event-Free and Overall Survival in Patients with Advanced Indolent B Cell Malignancies: CALGB 109901
118. Comparison of Outcomes after Transplantation of G-CSF–Stimulated Bone Marrow Grafts versus Bone Marrow or Peripheral Blood Grafts from HLA-Matched Sibling Donors for Patients with Severe Aplastic Anemia
119. CTLA-4 Blockade following Relapse of Malignancy after Allogeneic Stem Cell Transplantation Is Associated with T Cell Activation But Not with Increased Levels of T Regulatory Cells
120. Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Patients with Hematologic Malignancies Who Relapse following Autologous Transplantation: A Multi-institutional Prospective Study from the Cancer and Leukemia Group B (CALGB trial 100002)
121. The Intensity of the Induction Regimen Does Not Affect Post-Transplant Survival Among Patients with Newly Diagnosed Mantle Cell Lymphoma
122. Optimizing Donor Selection for Haploidentical Transplantation Utilizing the Four-Group T Cell Epitope (TCE-4) Algorithm for Prediction of HLA-DPB1 Non-Permissive Mismatches
123. Impact of Choice of Induction Regimen on Overall Survival and Post-Remission Survival Among Older Adults with Acute Myeloid Leukemia
124. Recipient HLA-B Leader Genotype, and Its Relationship to Total KIR Missing Ligand, Informs Relapse and Survival Following Haploidentical Transplantation Using Post-Transplant Cyclophosphamide
125. High-Dose Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Conditioning Prior to Autologous Transplantation for Patients with Multiple Myeloma: Results of a Prospective Phase II Trial
126. Post-Relapse Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post Transplant Cyclophosphamide (PTCY): Potential Impact of DLI Post-Relapse
127. Barriers to and Results of Allogeneic Hematopoietic Transplantation for Adult Patients with Sickle Cell Disease: An Analysis of Referrals and Transplants Performed at a Single Center in the Era of Haploidentical Donor Use
128. Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study
129. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improves Transplant Outcomes in Older MDS Patients
130. Outcome of Patients With IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Retrospective CIBMTR Study
131. Outcome of Transplantation for Myelofibrosis
132. Race and Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
133. Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study
134. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation
135. Autologous Hematopoietic Stem Cell Transplantation as an Intensive Consolidation Therapy for Adult Patients in Remission from Acute Myelogenous Leukemia
136. In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burden
137. Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia
138. Comparable Outcomes in Nonsecretory and Secretory Multiple Myeloma after Autologous Stem Cell Transplantation
139. Comparison of Twin and Autologous Transplants for Multiple Myeloma
140. Second Autologous Stem Cell Transplantation for Relapsed Lymphoma after a Prior Autologous Transplant
141. HLA-Identical Sibling Allogeneic Transplants versus Chemotherapy in Acute Myelogenous Leukemia with t(8;21) in First Complete Remission: Collaborative Study between the German AML Intergroup and CIBMTR
142. A Phase II Trial of Melphalan Based Reduced-Intensity Conditioning for Transplantation of T-Replete HLA-Haploidentical Peripheral Blood Stem Cells with Posttransplant Cyclophosphamide in Patients with Hematologic Malignancies
143. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis
144. Extracorporeal Photopheresis (ECP) Improves Overall Survival in the Treatment of Steroid Refractory Acute Graft-Versus-Host Disease (SR aGVHD)
145. CD34+ Selected Hematopoietic Cell Boosts (HCB) for Treatment of Refractory Cytopenia Following T-Replete HLA-Haploidentical Transplantation
146. Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study
147. Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings
148. Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience
149. 1177. Rapid, Non-invasive Detection of Invasive Mucormycosis Caused by Syncephalastrum monosporum Using Next-Generation Sequencing of Circulating Microbial Cell-free DNA in Plasma
150. 751. Karius Cell-Free DNA Metagenomic Assay of Plasma Detects Pulmonary and Disseminated Trichosporon Infections in Patients with Hematological Malignancies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.